[Myasthenia gravis; therapy]. 1952

J BLEGER

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis

Related Publications

J BLEGER
February 1977, Revista clinica espanola,
J BLEGER
March 1957, Schweizerische medizinische Wochenschrift,
J BLEGER
August 2001, Praxis,
J BLEGER
September 1953, Neurology,
J BLEGER
April 1959, Bulletin of the New York Academy of Medicine,
J BLEGER
March 1986, Deutsche medizinische Wochenschrift (1946),
J BLEGER
January 1971, Nihon rinsho. Japanese journal of clinical medicine,
J BLEGER
June 1957, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
J BLEGER
August 1977, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!